A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity
Phase of Trial: Phase III
Latest Information Update: 04 May 2017
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Rhythm
- 04 May 2017 Status changed from planning to recruiting, according to a Rhythm media release.
- 20 Feb 2017 New trial record
- 16 Feb 2017 According to a Rhythm Pharmaceuticals media release, this trial is expected to initiate in 2017.